Managing specific symptoms in people with multiple sclerosis

International MS Journal

Volumn 12, Issue 2, 2005, Pages 60-68

  Henze, T ^a  

^a Klinik am Regenbogen   (Germany)

Author keywords

Bladder dysfunction; Fatigue; Multiple sclerosis; Pain; Spasticity; Symptomatic treatment

Indexed keywords

4 AMINOPYRIDINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA INTERFERON; BOTULINUM TOXIN A; CANNABINOID DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DANTROLENE; GABAPENTIN; GLATIRAMER; LAMOTRIGINE; LEVACECARNINE; MODAFINIL; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PARACETAMOL; TIZANIDINE; TOLPERISONE; TOPIRAMATE; TRIAMCINOLONE ACETONIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VASOPRESSIN;

CHRONIC PAIN; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; DRUG DEPENDENCE; FATIGUE; HUMAN; INFECTION; INJECTION SITE PAIN; MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; NEUROGENIC BLADDER; NEUROPATHIC PAIN; NOCTURIA; PALLIATIVE THERAPY; PARALYSIS; PHYSIOTHERAPY; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SPASTICITY; SYMPTOMATOLOGY; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; PAIN;

FATIGUE; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN; URINARY BLADDER, NEUROGENIC;

EID: 33644921478     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Goodin DS, Frohman EM, Garmany GP, Jr, Halper J, Likosky WH, Lublin FD et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
2. Multiple Sclerosis Treatment Consensus Group (MSTCG) of the German MS Society. Symptomatic treatment of multiple sclerosis. Nervenarzt 2004; 75 (Suppl 1): S2-S39.
3. Bobath B. Adult Hemiplegia: Evaluation and Treatment, 3rd edn. Amsterdam: Elsevier, 1991.
4. Brunnstrom S. Movement Therapy in Hemiplegia. New York: Harper & Row, 1970.
5. Vojta V, Peters A. Das Vojta-Prinzip. Berlin Heidelberg, New York: Springer, 1992.
6. Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran J, Pickersgill TP et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 174-179.
7. Hesse S, Konrad M, Uhlenbrock D. Treadmill walking with partial body weight support versus floor walking in hemiparetic subjects. Arch Phys Med Rehabil 1999; 80: 421-427.
8. Nuyens GE, De Weerdt WJ, Spaepen AJ, Jr, Kiekens C, Feys HM. Reduction of spastic hypertonia during repeated passive knee movements in stroke patients. Arch Phys Med Rehabil 2002; 83: 930-935.
9. Allison SC, Abraham LD. Sensitivity of qualitative and quantitative spasticity measures to clinical treatment with cryotherapy. Int J Rehabil Res 2001; 24: 15-24.
10. Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler 2002; 8: 319-329.
11. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001332. Available at: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD001332/frame.html. Last accessed 3 June 2005.
12. Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81: 164-169.
13. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997; 78: 521-524.
14. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526.
15. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, van Loenen AC, Staats PG et al. Safety, tolerabilily, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-1407.
16. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-712.
17. Snow BJ, Tsui JK, Bhalt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512-515.
18. Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63: 204-209.
19. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-1521.
20. Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N et al. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neurol Sci 2003; 211: 81-84.
21. Multiple Sclerosis Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America, 1999.
22. Krupp LB, La Rocca NG, Muir-Nash J, Steinberg AD. The Fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
23. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18 (Suppl 1): 79-83.
24. Beenakker EA, Oparina TI, Hartgring A, Teelken A, Arutjunyan AV, De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 2001; 57: 892-894.
25. NASA MS Cooling Study Group. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 2003; 60: 1955-1960.
26. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002; 8: 161-168.
27. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-1961.
28. Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001; 7: 354-358.
29. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179-183.
30. Zifko UA, Rupp M, Schwarz S, Zifko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002; 249: 983-987.
31. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004; 218: 103-108.
32. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. New aspects and practical application. J Neurol 2004; 251: 1329-1339.
33. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. The Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD001133. Available at: http://www.mrw.interscience. wiley.com/cochrane/clsysrev/ articles/CD001133/ frame.html. Last accessed 3 June 2005.
34. DMKG Study Group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003; 250: 542-545.
35. Jho HD, Lunsford LD. Percutaneous retrogasserian glycerol rhizotomy. Current technique and results. Neurosurg Clin N Am 1997; 8: 63-74.
36. Kondziolka D, Lunsford LD, Bissonette DJ. Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia. Can J Neurol Sci 1994; 21: 137-140.
37. Broggi G, Ferroli P, Franzini A, Pluderi M, La Mantia L, Milanese C. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet 1999; 354: 1878-1882.
38. Huang E, Teh BS, Zeck O, Woo SY, Lu HH, Chiu JK et al. Gamma knife radiosurgery for treatment of trigeminal neuralgia in multiple sclerosis patients. Stereotact Funct Neurosurg 2002; 79: 44-50.
39. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999; 162: 162-168.
40. Backonja M. Anticonvulsants for the treatment of neuropathic pain syndromes. Curr Pain Headache Rep 2003; 7: 39-42.
41. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000; 55: 915-920.
42. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology 2002; 58: 554-563.
43. Furlan AD, Brosseau L, Imamura M, Irvin E. Massage for low-back pain. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD001929. Available at: http://www.mrw.interscience. wiley.com/cochrane/ clsysrev/ articles/CD001929/frame.hfml. Last accessed 3 June 2005.
44. Milne S, Welch V, Brosseau L, Saginur M, Shea B, Tugwell P, Wells G. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. The Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD003008. Available at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/ articles/CD003008/frame.html. Last accessed 3 June 2005.
45. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain. Phys Ther 2001; 81: 1719-1730.
46. Arzneimittelkommission der Deutschen Arzteschaft: Leitlinien zur Therapie degenerativer Gelenkerkrankungen (in German). Available ah www.akdae.de/35/ 10Hefte/ 87_Gelenkerkrankungen_2001_2Auflage.pdf. Last accessed 8 February 2005.
47. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and Ibuprofen are equally effective in managing flulike symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Mult Scler 2002; 8: 15-18.
48. Rio J, Nos C, Bonaventura I, Arroyo R, Genis D, Sureda B et al. Corticosteroids, ibuprofen, and acetaminophen for IFN beta-1a flu symptoms in MS. A randomized trial. Neurology 2004; 63: 525-528.
49. Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. The Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD002113. Available at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002113/frame. html. Last accessed 3 June 2005.
50. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. The Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD001308. Available at: http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD001308/frame.html. Last accessed 3 June 2005.
51. de Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999; 99: 61-64.
52. Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 1997; 11: 211-219.
53. Primus G, Kramer G. Maximal external electrical stimulation for treatment of neurogenic or non-neurogenic urgency and/or urge incontinence. Neurourol Urodyn 1996; 15: 187-194.
54. Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003781. Available at: htlp://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003781/frame. html. Last accessed 3 June 2005.
55. Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safely of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 1999; 37: 196-200.
56. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 65: 778-780.
57. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B et al. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital trad infections. Eur Urol 2001; 40: 576-588.
58. Banovac K, Wade N, Gonzalez F, Walsh B, Rhamy RK. Decreased incidence of urinary tract infections in patients with spinal cord injury, effect of methenamine. J Am Paraplegia Soc 1991; 14: 52-54.
59. Funfstuck R, Straube E, Schildbach O, Tietz U. Prävention von Rezidivinfektionen durch L-Methionin bei Patienten mit rezidivierenden Harnwegsinfektionen (in German). Med Klin 1997; 92: 574-581.
60. Morton SC, Shekelle PG, Adams JL, Bennett C, Dobkin BH, Montgomerie J et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002; 83: 129-138.
61. Oakeshott P, Hunt GM. Intermittent self catheterization for patients with urinary incontinence or difficulty emptying the bladder. Br J Gen Pract 1992; 42: 253-255.
62. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005; 24: 2-12.